The Group posted a loss of £1.8 million, up from £0.4 million in the same period last year LONDON: ImmuPharma PLC (LSE:IMM), a specialist in drug discovery and development, reported a widened interim loss for the six months ended June…
LONDON: ImmuPharma PLC, a specialist drug discovery and development company, has announced a positive and comprehensive update on its financial situation and its portfolio of products. The company, which is listed on the London Stock Exchange’s AIM market, said it…
LONDON, UK: ImmuPharma Plc, the specialist drug discovery and development company, has signed a 2-year collaboration agreement with Imperial College London. Under the collaboration, Imperial College will provide significant intellectual input and guidance on a number of innovative peptide assets…